AstraZeneca's Iressa Produces Effect In Subpopulation, ASCO Data Show
This article was originally published in The Pink Sheet Daily
Executive Summary
Initial Phase II study shows 62% response rate in Korean, non-smoking females with non-small cell lung cancer. Identification of Iressa (gefitinib) responders and the role of EGFR mutations are major themes at the American Society of Clinical Oncology annual meeting.
You may also be interested in...
FDA Drug Safety Changes Will Not Affect Oncology Therapies, Agency's Pazdur Says
FDA's safety overhaul "will not tamper with" drugs for life-threatening conditions, Office of Oncology Drug Products Director Pazdur tells the American Society of Clinical Oncology annual meeting. FDAer suggests the cancer community could provide insight into improved safety surveillance.
FDA Drug Safety Changes Will Not Affect Oncology Therapies, Agency's Pazdur Says
FDA's safety overhaul "will not tamper with" drugs for life-threatening conditions, Office of Oncology Drug Products Director Pazdur tells the American Society of Clinical Oncology annual meeting. FDAer suggests the cancer community could provide insight into improved safety surveillance.
Additional Iressa Study Closed Due To Lack Of Survival Benefit
Data monitoring committee recommends closing National Cancer Institute-sponsored trial studying gefitinib as a maintenance therapy in non-small cell lung cancer patients who responded to chemo. NCI trial is the second study in recent months in which Iressa failed to demonstrate a survival benefit.